Calidi Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Calidi Biotherapeutics, Inc. (CLDI) on October 18, 2024. The Company is incorporated in Delaware and operates as an emerging growth company. The report serves to disclose a Regulation FD update made available on the Company's website on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The sole material event reported is the release of an updated corporate presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing references an updated presentation furnished as Exhibit 99.1, which likely contains management commentary, outlook, or strategic updates. However, the specific content of that presentation is not included in this text. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the content.
Key Facts for Investor Verification
- Review Exhibit 99.1 (the attached presentation) for specific details on the Company's strategy, pipeline, or financial outlook.
- Verify the Company's status as an emerging growth company and its implications for financial reporting.
- Note that the information in this 8-K is not incorporated by reference into other filings unless expressly stated.
- Confirm the trading symbols: Common Stock (CLDI) and Warrants (CLDI WS) on NYSE American LLC.